Welcome to our dedicated page for Alkermes plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Alkermes Inc. plc (NASDAQ: ALKS) is a global biopharmaceutical company dedicated to developing innovative medicines for treating central nervous system (CNS) diseases. Headquartered in Dublin, Ireland, Alkermes has a significant presence in the United States with a research and development center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company’s mission is to leverage its proprietary technologies to create and commercialize pharmaceutical products that address unmet medical needs in conditions such as schizophrenia, depression, addiction, and multiple sclerosis.
Alkermes’ diversified product portfolio includes notable medications like LYBALVI®, ARISTADA®, and VIVITROL®. These products are pivotal in the treatment of mental health disorders and substance abuse, demonstrating the company's commitment to enhancing patient outcomes. LYBALVI®, a combination of olanzapine and samidorphan, is used for treating schizophrenia and bipolar I disorder. ARISTADA® is an extended-release injectable suspension for schizophrenia, and VIVITROL® is used for alcohol and opioid dependence.
The company's robust clinical pipeline features breakthrough candidates such as ALKS 2680, an investigational orexin 2 receptor agonist targeting narcolepsy. Recent study results announced in early 2024 have shown promising improvements in wakefulness for patients with narcolepsy type 2 and idiopathic hypersomnia, validating the potential of ALKS 2680 to address critical gaps in treatment.
Alkermes has also engaged in significant corporate developments, including the sale of its Athlone, Ireland facility to Novo Nordisk, aimed at increasing operational efficiency. Financially, the company reported total revenues of $1.66 billion for 2023, with a net income of $356 million, emphasizing strong growth and profitability. The company's strategic focus on neuroscience and operational efficiency is expected to drive sustained profitability and innovation in treating CNS disorders.
For more detailed information about Alkermes’ products, clinical trials, and corporate strategies, you can visit their official website at www.alkermes.com.
Alkermes plc (Nasdaq: ALKS) announced it will present a poster on nemvaleukin alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting from Nov. 10-14, 2021. The poster will feature data from the ION-01 study, a phase 2 trial assessing the combination of intravenous nemvaleukin with pembrolizumab in patients with head and neck squamous cell carcinoma. The presentation by Brian Gastman, M.D., is scheduled for Nov. 13, 2021, with the poster available on the SITC platform from Nov. 12, 2021.
Alkermes plc (Nasdaq: ALKS) announced its participation in several scientific conferences to present research from its psychiatry and addiction portfolios this fall. The events include Psych Congress (Oct. 29-Nov. 1), ISAD Conference (Nov. 3-4), and NEI Congress (Nov. 4-7). Key presentations will cover topics such as the impact of COVID-19 on clinic operations, opioid prescription patterns among patients, and a benefit-risk assessment of olanzapine combined with samidorphan for treating schizophrenia and bipolar I disorder. Alkermes continues its commitment to advancing care for patients with these serious conditions.
Alkermes plc (Nasdaq: ALKS) reported third-quarter 2021 revenues of $294.1 million, up from $265.0 million the previous year, with net sales of proprietary products reaching $157.7 million. The launch of LYBALVI expanded their psychiatry franchise. However, total operating expenses rose to $313.8 million, resulting in a GAAP net loss of $29.0 million. Despite the loss, non-GAAP net income was $23.6 million. Alkermes maintains its 2021 financial guidance, contingent on improving patient access and treatment normalization.
Alkermes plc (Nasdaq: ALKS) has launched ARTISTRY-7, a global phase 3 trial for the intravenous administration of nemvaleukin alfa combined with pembrolizumab in treating platinum-resistant ovarian cancer. This investigational immunotherapy aims to fulfill a significant unmet medical need. The trial will enroll approximately 376 patients, focusing on progression-free survival as the primary endpoint. The U.S. FDA has granted Fast Track designation to this combination therapy, underscoring its potential. Alkermes looks to build on previous positive responses observed in earlier studies.
Alkermes (Nasdaq: ALKS) announced the FDA has granted Fast Track designation for nemvaleukin alfa, an investigational immunotherapy, in combination with pembrolizumab for platinum-resistant ovarian cancer. This designation aims to expedite development and review processes for therapies addressing serious medical needs. The announcement includes plans to initiate the ARTISTRY-7 phase 3 trial for this treatment, which has potential significance for patients lacking approved options. Fast Track status allows for frequent communication with the FDA and the possibility of rolling reviews.
Alkermes plc (Nasdaq: ALKS) will host a conference call on October 27, 2021, at 8:00 a.m. ET to discuss its third-quarter 2021 financial results. The event will also include an update on the company's activities. Investors can access the webcast via Alkermes' website, and a replay will be available shortly after the call. Alkermes is a global biopharmaceutical company focused on innovative medicines addressing neuroscience and oncology, with products for addiction, schizophrenia, and bipolar disorder.
On October 18, 2021, Alkermes plc (Nasdaq: ALKS) announced the commercial availability of LYBALVI® (olanzapine and samidorphan) in the U.S. for treating adults with schizophrenia and bipolar I disorder. LYBALVI is a once-daily oral atypical antipsychotic that combines olanzapine with samidorphan. The FDA approved it based on data from 27 clinical studies. Alkermes aims to engage healthcare providers to enhance patient access and awareness of this new treatment option, thus expanding its psychiatry franchise.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. ET. Investors can access the presentation via the Investors tab on www.alkermes.com, where it will be archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience and oncology, with products related to addiction and various mental health disorders.
Alkermes plc (Nasdaq: ALKS) announced two poster presentations regarding nemvaleukin alfa at the ESMO Virtual Congress from Sept. 16-21, 2021. The presentations focus on the ARTISTRY-6 global phase 2 trial evaluating nemvaleukin monotherapy for melanoma patients previously treated with anti-PD-(L)1 therapy, along with preclinical data on its efficacy in treating small cell lung cancer. The data aims to support registration in mucosal melanoma. Alkermes is exploring nemvaleukin's potential as a novel therapy for various tumor types.
FAQ
What is the current stock price of Alkermes plc (ALKS)?
What is the market cap of Alkermes plc (ALKS)?
What does Alkermes Inc. plc specialize in?
What are some key products of Alkermes?
Where is Alkermes headquartered?
What recent achievements has Alkermes announced?
How did Alkermes perform financially in 2023?
What strategic moves has Alkermes made recently?
What is ALKS 2680?
What initiatives support Alkermes' commitment to mental health?
How can I get more information about Alkermes?
What partnerships or collaborations is Alkermes involved in?
